DLL3 and small cell lung carcinoma: An ADC called rovalpituzumab tesirine (Rova-T) developed to target DLL3 has been evaluated in a phase I study as a frontline mono therapy or in combinations with cisplatin and etoposide for patients with extensive-stage SCLC (NCT02819999).